Capital and ownership
What a distressed gene therapy asset sale signals for pipeline value and strategic buyers.
What this edition helps you see
A concise weekly synthesis of what happened, why it matters, and where to read the underlying reporting.
Safety and oversight
How trial disclosures and monitoring choices can change the regulatory picture.
Editing durability
What one year of stable liver editing data adds to the durability conversation.
Read the published articles
The PDF bundles the same published articles and analysis. Read each original article here, then download the copy for later.
This collection curates public and third-party sources for information only. It may contain errors, omissions, interpretations, or outdated information. No warranties are given. It is not financial, investment, medical, legal, regulatory, tax, professional, or consulting advice, does not create a client relationship, and is not a substitute for original-source review or independent due diligence. Do not use it as the sole basis for a decision. Read the full notice.
Get Edition 02 free
Complete the form for the 40 page PDF, including the three signals, four published stories, and the decision context behind each one.
Your resource is ready
Download Edition 02 and keep the decision context close as you plan your next move.
Download Edition 02 PDF Join the GTC Expert Network. Members access the growing AAV to AI library in TopicBoard as new editions are added.